亚虹医药(688176) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter reached ¥86,170,827.01, representing a year-on-year increase of 47.41%[5] - The total profit for the period was a loss of ¥91,109,604.17, with a net profit attributable to shareholders of ¥-86,732,800.64[5] - Total revenue for the first three quarters of 2025 reached ¥216,408,302.14, a significant increase of 55.7% compared to ¥138,951,629.03 in the same period of 2024[21] - Net loss for the first three quarters of 2025 was ¥261,050,841.03, slightly improved from a net loss of ¥271,342,070.94 in the same period of 2024[22] - Basic earnings per share for the first three quarters of 2025 were -¥0.44, compared to -¥0.48 in the previous year[23] Research and Development - Research and development (R&D) expenses amounted to ¥53,359,320.94, which is a decrease of 17.96% compared to the previous year[6] - R&D expenses accounted for 61.92% of operating revenue in the current period, down by 49.34 percentage points year-on-year[6] - Research and development expenses were ¥169,848,302.99, a decrease of 22.4% from ¥219,040,308.86 in the previous year[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,148,699,982.48, a decrease of 3.34% from the previous year[6] - The net assets attributable to shareholders decreased by 11.42% to ¥1,744,502,159.34 compared to the end of the previous year[6] - Total assets decreased to ¥2,148,699,982.48 from ¥2,222,991,903.79, reflecting a decline of 3.3%[19] - Total liabilities increased to ¥412,493,308.25, up from ¥252,618,105.29, marking a rise of 63.4%[19] - The company's equity attributable to shareholders decreased to ¥1,744,502,159.34 from ¥1,969,405,336.09, a decline of 11.4%[19] Cash Flow - The company reported a net cash flow from operating activities of ¥-301,798,901.12 for the year-to-date period[5] - Cash inflow from operating activities for the first three quarters of 2025 reached approximately $216.36 million, a significant increase from $128.58 million in the same period of 2024, representing a growth of about 68.2%[25] - The net cash flow from operating activities was negative at approximately -$301.80 million for 2025, compared to -$325.16 million in 2024, showing an improvement of about 7.1%[26] - The total cash outflow from operating activities was approximately $518.16 million in 2025, compared to $453.74 million in 2024, marking an increase of about 14.2%[26] Investments - Cash inflow from investment activities totaled approximately $4.56 billion in 2025, compared to $3.40 billion in 2024, indicating an increase of about 34.1%[26] - The net cash flow from investment activities was negative at approximately -$60.29 million in 2025, contrasting with a positive $443.76 million in 2024, reflecting a significant decline[26] - The company received approximately $8.07 million from investment in subsidiaries in 2025, while no such income was recorded in 2024[26] - The company reported a cash inflow from the recovery of investments of approximately $4.56 billion in 2025, compared to $3.40 billion in 2024, indicating a strong performance in investment recovery[26] Shareholder Information - The company has a total of 8,667,675 shares in its repurchase account, accounting for 1.52% of total shares[14] - The top shareholder, Pan-Scientific Holdings Co., Ltd., holds 31,858,481 shares, representing a significant portion of the company's equity[14] - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[15] Financial Statements - The financial statements for the quarter are unaudited, indicating that the figures are subject to final review and adjustments[17]